Enovix Corporation vs Merck & Co., Inc. — how do they compare? Enovix Corporation trades at $4.87 (market cap $1.01B), while Merck & Co., Inc. trades at $130.21 (market cap $323.00B). The key difference: Merck & Co., Inc. is far larger — about 319.8× Enovix Corporation's market cap, and Merck & Co., Inc. pays a 2.6% dividend while Enovix Corporation pays none. Which is the better fit depends on your goals.
| ENVX | MRK | |
|---|---|---|
Market Cap | $1.01B | $323.00B |
Sector | Technology | Health |
52-Week High | $13.19 | $131.84 |
52-Week Low | $3.68 | $77.60 |
Enterprise Value | $1.03B | $369.77B |
Dividend Yield | — | 2.6% |
Signals from Pluang's Aura AI — not financial advice
ENVX trades at $4.70, up 10.33% today, with a bullish technical signal despite negative profitability. Recent earnings beats and a $12.38 consensus price target suggest upside potential. The company is ramping production of advanced silicon-anode batteries, with key developments including a new COO appointment and upcoming Q2 2026 results on August 12, 2026.
Outlook remains speculative with high revenue growth potential but persistent losses; risks include cash burn and competitive pressures. Analyst sentiment is positive (75% buy ratings), but investors should weigh the long-term growth story against near-term financial challenges.
MRK trades at $130.90, up 1.81% today, with a bullish technical signal and strong institutional buying interest. The stock shows robust fundamentals with revenue of $65.01B in 2025 and net income of $18.25B, though a high P/E of 104.74 indicates premium valuation. Recent news highlights Merck's acquisition of Terns Pharmaceuticals to bolster its oncology pipeline, reflecting strategic growth initiatives.
Outlook is positive with a consensus price target of $139.90, offering ~7% upside, supported by 67.57% analyst buy ratings. Risks include integration challenges from acquisitions and patent expirations, but strong cash flow and dividend payments provide stability. Investors may find value in Merck's market leadership and pipeline expansion, though valuation metrics warrant caution.
Trailing returns across standard periods
Latest headlines on both assets
Enovix designs and manufactures advanced silicon-anode lithium-ion batteries. Its technology aims to provide high energy density and improved performance for mobile devices and consumer electronics.
Read more on ENVX →Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →